Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 15,230 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 15,230 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 17,126 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 17,126 · Balance 17,126 F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 17,126 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001805097-26-000001 · form4-02182026_120215.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,126 Underlying: Common Stock · 17,126 shares Expires 2036-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000098 · wk-form4_1755118547.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000098 · wk-form4_1755118547.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 15,768 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,816 Underlying: Common stock · 2,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 20,491 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003516 · form4-02102025_100220.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,491 Underlying: Common Stock · 20,491 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $25.99 | $0.00 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · derivative · entry 9 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,947 Underlying: Common stock · 10,000 shares Expires 2032-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,500 | $59.21 | $88,815.00 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 7 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,992 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,929 | $58.57 | $288,691.53 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 6 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,492 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 3,571 | $57.24 | $204,404.04 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 5 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,421 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 10,000 | $25.99 | $259,900.00 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $25.99 | $0.00 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · derivative · entry 8 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,947 Underlying: Common stock · 10,000 shares Expires 2032-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,868 | $54.41 | $101,637.88 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,992 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 8,132 | $53.32 | $433,598.24 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,860 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 10,000 | $25.99 | $259,900.00 |
DisclosureSEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 00:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,106 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001415889-24-024990 · form4-10112024_121018.xml · derivative · entry 5 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,322 Underlying: Common Stock · 4,106 shares Expires 2032-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F4 · derivative.exercise_date: The option, originally for 32,849 shares, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 00:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 6,314 | $0.00 Strike: $19.68 | $0.00 |
DisclosureSEC source: 0001415889-24-024990 · form4-10112024_121018.xml · derivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,428 Underlying: Common Stock · 6,314 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 00:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,420 | $28.17 | $293,557.45 |
DisclosureSEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.00 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 00:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,106 | $5.52 | $22,665.12 |
DisclosureSEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 00:36 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 6,314 | $19.68 | $124,259.52 |
DisclosureSEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| August 11, 2024 Filed Aug 13, 2024 20:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000127 · wk-form4_1723580129.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,302 Underlying: Common stock · 2,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 11, 2024 Filed Aug 13, 2024 20:15 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000127 · wk-form4_1723580129.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 11,774 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001439222-24-000106 · wk-form4_1719259815.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000106 · wk-form4_1719259815.xml · derivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000085 · wk-form4_1718659363.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000085 · wk-form4_1718659363.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 4,580 | $0.00 Strike: $19.68 | $0.00 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 10 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,742 Underlying: Common Stock · 4,580 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 48,820 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 9 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,820 shares Expires 2028-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,068 | $25.21 | $77,342.44 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 7 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 20,032 | $25.00 | $500,701.84 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 6 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,409 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 30,300 | $23.14 | $701,023.83 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 5 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,441 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 4,580 | $19.68 | $90,134.40 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 48,820 | $12.60 | $615,132.00 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 8 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,820 Underlying: Common Stock · 13,600 shares Expires 2028-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 13,600 | $21.01 | $285,744.16 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 22:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 13,600 | $12.60 | $171,360.00 |
DisclosureSEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| April 04, 2024 Filed Apr 9, 2024 00:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,485 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001415889-24-010520 · form4-04092024_120438.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,420 Underlying: Common Stock · 3,485 shares Expires 2028-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 04, 2024 Filed Apr 9, 2024 00:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,485 | $19.15 | $66,729.39 |
DisclosureSEC source: 0001415889-24-010520 · form4-04092024_120438.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.05 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 04, 2024 Filed Apr 9, 2024 00:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,485 | $12.60 | $43,911.00 |
DisclosureSEC source: 0001415889-24-010520 · form4-04092024_120438.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 01:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,143 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001415889-24-010232 · form4-04042024_010458.xml · derivative · entry 5 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 3,143 shares Expires 2032-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F5 · derivative.exercise_date: The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter. F4 · balance_after: The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split"). Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 01:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 94 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001415889-24-010232 · form4-04042024_010458.xml · derivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,905 Underlying: Common Stock · 94 shares Expires 2028-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. F4 · balance_after: The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split"). Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 01:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,237 | $19.08 | $61,758.40 |
DisclosureSEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,341 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 01:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,143 | $5.52 | $17,349.36 |
DisclosureSEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 01:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 94 | $12.60 | $1,184.40 |
DisclosureSEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.